ALB and Ascites: The ANSWER randomised-controlled trial (RCT) has shown that long-term albumin (LTA) treatment in patients with cirrhosis and uncomplicated ascites improves 18-month overall survival rates, facilitates the management of ascites, and lowers the incidence of severe complications, thus reducing hospitalizations and improving patients’ quality of life.1